by Dr. James W. Stark

11/25/14 - Plegridy was recently approved by the FDA for the treatment of relapsing forms of MS and is now available for use. Plegridy is another interferon, specifically pegylated interferon B-1a. It is similar to other interferons currently available but is administered every two weeks by a subcutaneous injection. Side effects were similar to other interferons, however, because it is administered every two weeks, side effects were seen less frequently than... more

11/17/14 - Dr. Armistead Williams has been named by New York Super Doctors® as one of the rising star doctors in New York for 2014. The number of doctors receiving this honor is limited to approximately five percent of the region’s active physicians.   Each year, Key Professional Media undertakes a rigorous multi-phase selection process that includes a survey of doctors, independent evaluation of candidates by the research staff, a peer review of candidates by practice area and a good-... more

10/27/14 - The following is a brief review of some future MS therapies presented by our MS Specialists during the Neurology Roundtable Discussion at the 17th Annual Tisch MS Patient Symposium: Siponimod is an oral medication in development that is in the same class of drugs as Fingolimod, but may have fewer associated adverse events. Ocrelizumab is very similar to Rituximab, but will be much easier to obtain approval from insurance companies when it is FDA-approved for MS. Daclizumab is a... more

Thank you to all who attended the 17th Annual Tisch MS Research Patient Symposium.  In response to your requests, a review of the material presented will be posted on this website and appear in the next issue of our newsletter, Healing MS.